Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.
Biswas AK, Han S, Tai Y, Ma W, Coker C, Quinn SA, Shakri AR, Zhong TJ, Scholze H, Lagos GG, Mela A, Manova-Todorova K, de Stanchina E, Ferrando AA, Mendelsohn C, Canoll P, Yu HA, Paik PK, Saqi A, Shu CA, Kris MG, Massague J, Acharyya S. Biswas AK, et al. Among authors: shu ca. Cancer Discov. 2022 Apr 1;12(4):1002-1021. doi: 10.1158/2159-8290.CD-21-0910. Cancer Discov. 2022. PMID: 35078784 Free PMC article.
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A. Heymann JJ, et al. Among authors: shu ca. Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12. Cancer Cytopathol. 2017. PMID: 29024471 Free article.
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. Sabari JK, et al. Among authors: shu ca. Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334. Ann Oncol. 2018. PMID: 30165371 Free PMC article.
Synchronous Pulmonary Adenocarcinomas.
Pagan CA, Shu CA, Crapanzano JP, Lagos GG, Stoopler MB, Rizvi NA, Heymann JJ, Sonett JR, Fernandes H, Saqi A. Pagan CA, et al. Among authors: shu ca. Am J Clin Pathol. 2020 Jun 8;154(1):57-69. doi: 10.1093/ajcp/aqaa023. Am J Clin Pathol. 2020. PMID: 32146481
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, Lanuti M, D'Ovidio F, Bacchetta M, Sonett JR, Saqi A, Rizvi NA. Shu CA, et al. Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7. Lancet Oncol. 2020. PMID: 32386568 Clinical Trial.
39 results